The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010: (Published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166)
Abstract
Nonalcoholic fatty liver disease (NAFLD) is an acquired metabolic stress-induced liver disease associated with insulin resistance (IR) and genetic susceptibility, sharing histological similarities with alcoholic liver disease (ALD) in the absence of substantial alcohol consumption or other causes of liver disease. The spectrum of NAFLD is from simple steatosis to nonalcoholic steatohepatitis (NASH) and eventually cirrhosis and hepatocellular carcinoma.1, 2 NAFLD is one of the important public health problems worldwide in the 21st century and is also becoming more and more important in China.3 In order to further normalize the diagnosis and management of NAFLD, the Chinese National Consensus Workshop on NAFLD organized experts in this field to update the Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases formulated in 2006 with reference to the latest worldwide research findings and related diagnosis and treatment consensus and in line with the principles of evidence-based medicine.4-9 The evidence bases are categorized into three grades and five levels,11 presented as roman digits in parentheses (Table 1). The aim of this guideline is to help physicians to make correct decision in diagnosing and treating NAFLD. This guideline is not a mandatory standard and cannot involve or resolve all issues in the diagnosis and treatment program of NAFLD. Clinicians facing a specific patient should be able to make a reasonable diagnostic and therapeutic scheme based on the full understanding of the best clinical evidence and available medical resources and the comprehensive consideration of patient's specific condition and wishes, and in accordance with their own knowledge and experience. The research work on NAFLD has been advancing rapidly, so the guidelines should be updated and improved continually based on the progress of the discipline and clinical requirements in near future. NAFLD is now recognized as one of the most common causes of minor serum aminotransferase elevations and chronic liver diseases in developed countries such as Europe and America, and the prevalence of NAFLD is 20–33% in adults in the general population, among which NASH and cirrhosis account for 10–20% and 2–3%, respectively.1, 2, 12 The prevalence of simple steatosis, NASH and cirrhosis in obese patients was 60–90%, 20–25% and 2–8%, respectively. The prevalence of NASH in patients with type 2 diabetes mellitus (T2DM) and hyperlipidemia were 28–55% and 27–92%, respectively.1, 2, 12, 13 In parallel with the epidemic of obesity and metabolic syndrome worldwide, the prevalence of NAFLD in Asian countries has increased rapidly with a trend to younger patients during the last two decades. The prevalence of NAFLD was about 15% in adults in Shanghai, Guangzhou and Hong Kong.3 The risk factors for NAFLD include a high-fat diet, a high-calorific diet, a sedentary lifestyle, insulin resistance, metabolic syndrome and its components (obesity, hypertension, dyslipidemia and T2DM).3, 12, 13 Although alcohol abuse and hepatitis C virus (HCV) infection are closely associated with steatosis, the global epidemic of fatty liver is mainly correlated with the rapid increase in the epidemic of obesity.3, 12, 14 NAFLD patients with normal body mass index (BMI) or a normal waist circumference, or both, are not uncommon in Asia–Pacific regions, even when the criteria put forth by the World Health Organization regional office for the western Pacific region were used to diagnose obesity.3, 12, 13 A recent short-term weight gain and an increased waist circumference may be a cause of NAFLD and waist circumference predicts the presence of a fatty liver more accurately than BMI.3, 12, 13 Steatosis in patients with chronic HCV genotype 1 and 4 infection and hepatitis B virus (HBV) infection is highly likely to be related to insulin resistance and metabolic disorders and NAFLD is a common cause of minor serum aminotransferase elevation in hepatitis B surface antigen (HBsAg)-positive patients with serum HBV DNA level below 104 IU/mL.3, 4, 16 The long-term liver-related prognosis of patients with NAFLD depends mainly on its histological type as shown by a liver biopsy at presentation. Simple steatosis develops slowly and the incidence of cirrhosis is low (0.6–3%) after 10 to 20 years follow up; however, the rate of cirrhosis reaches 15–25% within 10 to 15 years in NASH patients.1, 2 Some markers, including age over 50 years, obesity (especially visceral obesity), hypertension, T2DM, alanine aminotransferase (ALT) elevation, aspartate aminotransferase (AST)/ALT ratio greater than 1, and a decrease of platelet count are risk factors for NASH and advanced fibrosis.1, 2, 9, 17 During the chronic protracted course of NAFLD, NASH is an inevitable stage in the development of simple steatosis into cirrhosis.1, 2 Compared to chronic hepatic C and alcoholic hepatitis, the liver fibrosis of patients with NASH progresses relatively slowly and decompensated cir
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Non-alcoholic fatty liver disease: The mist gradually clears
de Alwis, N. M. W., & Day, C. P. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.009 · Cited by 603
Vuppalanchi, R., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22603 · Cited by 563
Farrell, G. C., Chitturi, S., Lau, G. K., Sollano, J. D., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05002.x · Cited by 517
Epidemiology of non-alcoholic fatty liver disease in China
Fan, J.-G., & Farrell, G. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.010 · Cited by 502
Self-citationChronic hepatitis B: Update of recommendations† ‡
Lok, A. S. F., & McMahon, B. J. (2004) · Hepatology · doi:10.1002/hep.20110 · Cited by 500
Zivkovic, A. M., German, J. B., & Sanyal, A. J. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.2.285 · Cited by 422
Cited by
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease
Shen, F., Zheng, R.-D., Sun, X.-Q., Ding, W.-J., Wang, X.-Y., & Fan, J.-G. (2017) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/s1499-3872(17)60019-5 · Cited by 563
Self-citationZhou, D., Pan, Q., Xin, F.-Z., Zhang, R.-N., He, C.-X., Chen, G.-Y., Liu, C., Chen, Y.-W., & Fan, J.-G. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.60 · Cited by 441
Self-citationFrom NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 337
Lin, I.-T., Lee, M.-Y., Wang, C.-W., Wu, D.-W., & Chen, S.-C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18030857 · Cited by 69
Metadata
- Authors
- FAN, J. G., JIA, J. D., LI, Y. M., WANG, B. Y., LU, L. G., SHI, J. P., CHAN, L. Y., & CHINESE ASSOCIATION FOR THE STUDY OF LIVER DISEASE
- Venue
- Journal of Digestive Diseases
- Publisher
- Wiley
- Published
- 2011-01-30
- Volume
- 12
- Issue
- 1
- Pages
- 38-44
- ISSN
- 1751-2972 (ISSN-L)
- OpenAlex
- W3211528115
- Cited by
- 278
- References
- 28
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010: (Published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). https://app.cochat.ai/papers/10.1111/j.1751-2980.2010.00476.x
- The paper
- FAN, J. G., JIA, J. D., LI, Y. M., WANG, B. Y., LU, L. G., SHI, J. P., CHAN, L. Y., & CHINESE ASSOCIATION FOR THE STUDY OF LIVER DISEASE. (2011). Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010: (Published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). Journal of Digestive Diseases. https://doi.org/10.1111/j.1751-2980.2010.00476.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.